DXR - Daxor Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
12.48
+0.14 (+1.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.34
Open13.02
Bid11.00 x 800
Ask0.00 x 800
Day's Range11.75 - 13.02
52 Week Range4.30 - 19.95
Volume70,091
Avg. Volume61,306
Market Cap46.534M
Beta (3Y Monthly)-1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-01-05
1y Target Est30.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Daxor Corporation Addresses and Corrects Erroneous Seeking Alpha Healthcare News Editor Article of March 20, 2019

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today addressed and corrected an erroneous and misleading article published March 20, 2019, at 12:09pm eastern time on Seeking Alpha.com by Douglas W. House, Seeking Alpha News Editor, in which Mr. House erroneously stated, “Thinly traded nano cap Daxor (DXR -11.3%) is down on 50% higher volume, albeit on turnover of only 88K shares, following yesterday's corporate overview at the ROTH Conference in Southern California. Upon learning of Mr. House’s and Seeking Alpha’s publishing of this erroneous article and misstatements, Daxor contacted the editor to demand a retraction and correction that Daxor has one product, and moreover that it has generated no sales to date.

  • GlobeNewswire8 days ago

    Daxor Corporation to Present at the 31st Annual Roth Conference on March 19, 2019

    NEW YORK, March 15, 2019 -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood.

  • GlobeNewswire19 days ago

    Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2018. For the second straight year, Daxor reported that kit sales rose over 18% year-on-year in the cardiology segment, driven by increasing awareness of the value of blood volume analysis to improve heart failure outcomes through reduced mortality and readmissions. A landmark study on the use of the BVA-100 to guide heart failure treatment was published in the Journal of the American College of Cardiology – Heart Failure (“JACC-HF”) in November of 2018.

  • GlobeNewswire29 days ago

    New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation’s Blood Volume Analyzer (BVA-100®) in Critical Care

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new research from the University of Hawaii John A. Burns School of Medicine showing improved ease of use with the BVA-100 test by reducing the number of blood samples and that direct blood volume analysis provides clinicians with important information to inform better treatment decisions in the critically-ill. Three new studies were presented during the 48th Annual Society of Critical Care Medicine Congress in San Diego, CA. One study, “Reducing Blood Sampling for Circulating Blood Volume Determination: A Pilot Feasibility,” showed a 97% agreement in critically-ill cohorts whose blood volumes were compared using one blood draw versus five blood draws.

  • GlobeNewswirelast month

    Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the Society for Critical Care Medicine (SCCM) 48th Congress at the San Diego Convention Center in San Diego, CA from February 17-19th, 2019. Research from the University of Hawaii John A. Burns School of Medicine relating to the use of Daxor’s BVA-100 blood volume analyzer in Critical Care use is scheduled to be presented.

  • GlobeNewswire2 months ago

    Daxor Corporation Appoints Guido Manzo, Vice President of Sales

    Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Guido Manzo as Vice President of Sales. "Guido joins Daxor with 35 years of experience in medical sales and marketing focused on central lab and point-of-care testing.

  • GlobeNewswire2 months ago

    Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Aspirus Wausau Hospital in Wausau Wisconsin has acquired a BVA-100 Blood Volume Analyzer. Best known for its world-class cardiovascular program, Aspirus Wausau Hospital also provides leading edge cancer, trauma, women’s health, and spine and neurological care. Aspirus Wausau Hospital is the flagship of the Aspirus system that serves patients in 14 counties across northern and central Wisconsin, as well as the Upper Peninsula of Michigan.

  • GlobeNewswire4 months ago

    New Data Demonstrating the Clinical Utility of Daxor’s BVA-100 in Hypertension Management to be Presented at the American Heart Association’s Scientific Sessions 2018 

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the American Heart Association Scientific Sessions (AHA) at the McCormick Place Convention Center in Chicago, IL from November 10-12th, 2018. A presentation by Marat Fudim, M.D. of Duke University Medical Center demonstrating the clinical utility of blood volume analysis to help guide hypertension management will be featured.

  • GlobeNewswire4 months ago

    Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Army has selected it for a contract award to develop a blood volume analyzer for improving combat casualty care.

  • GlobeNewswire5 months ago

    CHF Solutions Initiates Strategic Collaboration with Daxor Corporation to Assist in the Management of Patients with Fluid Overload

    CHF Solutions, Inc. (CHFS) announced today that it has entered into a collaboration agreement with Daxor Corporation (DXR) to explore potential synergies between the company’s Aquadex FlexFlow® System and Daxor’s BVA-100 Blood Volume Analyzer.  The company believes that the two technologies can be used together to assess a patient’s fluid volume status and assist in informing on the clinical management of a fluid overloaded patient.

  • GlobeNewswire5 months ago

    Daxor Corporation Initiates Strategic Collaboration with CHF Solutions, Inc. to Manage Patients with Fluid Overload

    DAXOR CORPORATION (NYSE MKT: DXR) announced today that it has entered into an agreement with CHF Solutions (CHFS) to explore clinical synergies between the company’s BVA-100 Blood Volume Analyzer and CHF Solutions’ Aquadex FlexFlow® System to assess the benefit of combining Daxor’s fluid volume diagnostic with Aquadex FlexFlow therapy for the management of the fluid overloaded patient. “Daxor serves the same community of health care providers seeking to improve heart failure outcomes.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Daxor and Pfizer

    NEW YORK, NY / ACCESSWIRE / October 31, 2018 / Pharmaceutical giant Pfizer was little changed on Tuesday despite mixed earnings and news about price increases on drugs from its CEO Ian Read. Shares of Daxor Corporation were exploding as the company announcing the publication of promising data. Daxor Corporation shares were up nearly 87% on Tuesday on about 5.3 million shares traded.

  • GlobeNewswire5 months ago

    New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients

    Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality NEW YORK , Oct..

  • ACCESSWIRE9 months ago

    Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities

    On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Valeritas Holdings Inc. (NASDAQ: VLRX), Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), and Glaukos Corp. (NYSE: GKOS).